Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.